Skip to content
  • Forbes: Teixobactin and iChip promise hope against antibiotic resistance

    Forbes - 01/08/2015

    Teixobactin is the first new class of antibiotic announced in decades. That news and even more importantly, the elegant way it was discovered, are the most exciting news I’ve seen in some time.

    Antibiotic development has stagnated as pharmaceutical companies have instead turned their attention to the far more profitable ventures of drugs for chronic diseases, like diabetes or heart disease. Antibiotics had been relegated to the role of the unwanted stepchild, it seemed.

  • Cookies on Northeastern sites

    This website uses cookies and similar technologies to understand your use of our website and give you a better experience. By continuing to use the site or closing this banner without changing your cookie settings, you agree to our use of cookies and other technologies. To find out more about our use of cookies and how to change your settings, please go to our Privacy Statement.